КОРОНАВИРУС ИНФЕКЦИЯСИДАН КЕЙИН БЕМОРЛАРДА УГЛЕВОД АЛМАШИНУВИНИ БУЗИЛИШИ
Kalit so'zlar:
КОВИД-19, СAРСCоВ-2, қандли диабет, семизлик.Annotatsiya
КОВИД-19 пандемияси бутун дунёда давом етмоқда. Ҳозирда 590 миллионга яқин тасдиқланган ҳолатлар ва 6,44 миллион ўлим ҳолатлари мавжуд. Вирус тарқалишининг олдини олиш, патогенезини ўрганиш, олдини олиш учун ваксиналар яратиш, даволаш режалари ва даволаш мақсадларини белгилаш орқали ушбу касалликка қарши курашиш бўйича жадал ишлар олиб борилмоқда. Илгари диабетга чалинган одамларда CОВИД-19 нинг мураккаб курси ва прогнозлари ёмонроқ. Бундан ташқари, беморларга CОВИД-19 ташхиси қўйилгандан сўнг, уларда қандли диабетнинг юқори даражаси, шунингдек, қандли диабетнинг янги ҳолатлари қайд етилган. Илгари диабет ташхиси қўйилмаган беморларда CОВИД-19 туфайли гипергликемия ва бошқа асоратларни ривожланиш хавфи юқори. Ушбу мақоланинг мақсади CОВИД-19 епидемияси ва унинг қандли диабет билан икки жиҳатдан боғлиқлиги ҳақида биз билган нарсаларни умумлаштиришдир.
Foydalanilgan adabiyotlar
WHO. WHO Coronavirus Disease (COVID-19) Dashboard. [cited 8 August 2022]. Available from: https://covid19.who.int/
Wu, Z.; McGoogan, J.M. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreakin China: Summary of a Report of 72314 сases from the Chinese Center for Disease Control and Prevention. JAMA.2020; 323: 1239–1242.
Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020; 8:782–792.
Lim S, Bae JH, Kwon HS, Nauck MA. COVID-19 and diabetes mellitus: from pathophysiology to clinical management. Nat Rev Endocrinol. 2021; 17: 11-30.
Rubino F, Amiel SA, Zimmet P, et al. New-onset diabetes in Covid-19. NEngl J Med. 2020;383:789–790.
Dhan Bahadur Shrestha, Pravash Budhathoki, Sumit Raut, Sugat Adhikari, Prinska Ghimire, Sabin Thapaliya, Ali A Rabaan, Bibodh Jung Karki. New-onset diabetes in COVID-19 and clinical outcomes: A systematic review and meta-analysis. World J Virol. 2021; 10(5): 275-287.
Barbu MG, Thompson RJ, Thompson DC, Cretoiu D, Suciu N. The impact of SARS-CoV-2 on the most common comorbidities-a retrospective study on 814 COVID-19 deaths in Romania. Front Med (Lausanne). 2020;7:567199.
Erener S. Diabetes, infection risk and COVID-19. Mol Metab. 2020;39:101044
Shi Q, Zhang X, Jiang F, et al. Clinical characteristics and risk factors for mortality of COVID-19 patients with diabetes in Wuhan, China: a two-center, retrospective study. Diabetes Care. 2020;43:1382–1391.
Selvin E, Juraschek SP. Diabetes epidemiology in the COVID-19 pandemic. Diabetes Care. 2020;43:1690–1694.
Singh AK, Gupta R, Ghosh A, Misra A. Diabetes in COVID-19: prevalence,pathophysiology, prognosis and practical considerations. Diabetes Metab Syndr . 2020;14:303–310.
Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020;8:813–822.
Accili D. Can COVID-19 cause diabetes? Nat Metab. 2021;3:123–125.
Li J,Wang X, Chen J, Zuo X, Zhang H, Deng A. COVID-19 infection may cause ketosis and ketoacidosis. Diabetes Obes Metab 2020;22: 1935–1941.
Rawla P, Bandaru SS, Vellipuram AR. Review of infectious etiology of acute pancreatitis. Gastroenterol Res 2017;10:153–158.
Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ 2020;369:m1966.
Al-Sabah S, Al-Haddad M, Al-Youha S, Jamal M, Almazeedi S. COVID-19: impact of obesity and diabetes on disease severity. Clin Obes. 2020;10:e12414.
Khunti K, Del Prato S, Mathieu C, et al. COVID-19, Hyperglycemia, and New-Onset Diabetes. Diabetes Care. 2021; 44(12):2645-2655.
Sathish T, Kapoor N, Cao Y, et al. Proportion of newly diagnosed diabetes in COVID-19 patients: A systematic review and meta-analysis. Diabetes Obes Metab. 2021; 23(3):870-874.
Shrestha DB, Budhathoki P, Raut S et al. New- onset diabetes in COVID-19 and clinical outcomes: A systematic review and meta-analysis. World J Virol. 2021; 10(5):275-287.
Lazarus G, Audrey J, Wangsaputra VK, et al. High admission blood glucose independently predicts poor prognosis in COVID-19 patients: A systematic review and dose-response meta-analysis. Diabetes Res Clin Pract. 2021; 171:108561.
Apicella M, Campopiano MC, Mantuano M, Mazoni L, Coppelli A, Del Prato S. COVID-19 in people with diabetes: understanding the reasons for worse outcomes. Lancet Diabetes Endocrinol. 2020;8:782–792.
Yang JK, Jin JM, Liu S, et al. New onset COVID-19–related diabetes: an indicator of mortality. Med Rxiv. 2020 [preprint]. DOI: 0.1101/2020.04.08.20058040.
Li H, Tian S, Chen T, et al. Newly diagnosed diabetes is associated with a higher risk of mortality than known diabetes in hospitalized patients with COVID-19. Diabetes Obes Metab. 2020; 22:1897–1906.
Wang S, Ma P, Zhang S, et al. Fasting blood glucose at admission is an independent predictor for 28-day mortality in patients with COVID-19 without previous diagnosis of diabetes: a multi-centre retrospective study. Diabetologia 2020;63:2102–2111.
Временные методические рекомендации «Профилактика, диагностика и лечение новой коронавирусной инфекции (COVID-19). Версия 11» / Министерство здравоохранения РФ. – Москва: МЗ РФ, 2021. –– 225 c.
Sharma, S. Metformin in COVID-19: a possible role beyond diabetes / S. Sharma, A. Ray, B. Sadasivam // Diabetes Research and Clinical Practice. – 2020. – № 164. – P.108183.
Мetformin suppresses lipopolysaccharide (LPS)-induced inflammatory response in murine macrophages via activating transcription factor-3 (ATF-3) induction / J. Kim, H.J. Kwak, J.Y. Cha [et al.] // Journal of Biological Chemistry. – 2014. – Vol. 289, № 33. – P.23246–23255.
Use of dipeptidyl peptidase-4 inhibitors and prognosis of COVID-19 in hospitalized patients with type 2 diabetes: A propensity score analysis from the CORONADO study / R. Roussel, P. Darmon, M. Pichelin [et al.] // Diabetes Obesity Metabolism. – 2021. – № 23. – P.1162.
No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19 / J.H. Zhou, B. Wu, W.X. Wang [et al.] // World Journal of Clinical Cases. – 2020. –№ 8. – P.5576.
Exenatide once weekly versus placebo in Parkinson’s disease: a randomised, double-blind, placebo-controlled trial / D. Athauda [et al.] // Lancet. – 2017. – № 390. – P.1664–1675.
Glucose – lowering therapies in patients with type 2 diabetes and cardiovascular diseases / F. Prattichizzo [et al.] // European Journal of Preventive Cardiology. – 2019. – № 26. – P.73–80.
Practical recommendations for the management of diabetes in patients with COVID-19 / S.R. Bornstein, F. Rubino, K. Khunti [et al.] // Lancet Diabetes Endocrinology. – 2020. – Vol. 8, № 6. – P.546–550.
Cure, E. Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis / E. Cure, C.M. Cure // Diabetes & Metabolic Syndrome. – 2020. – № 14. – P.405–406.
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study / M. Kosiborod [et al.] // Diabetes Obesity Metabolism. – 2021. – Vol. 23, №.4. – P.886-896.
Acute kidney injury from SGLT2 inhibitors: potential mechanisms / K. Hahn, A.A. Ejaz, M. Kanbay [et al.] // Nature Reviews Nephrology. – 2016. – Vol. 12, № 12. – P.711–712.
Pharmacological (or Synthetic) and Nutritional Agonists of PPAR-γ as Candidates for Cytokine Storm Modulation in COVID-19 / C. Ciavarella, I. Motta, S. Valente, G. Pasquinelli // Disease. Molecules. – 2020. – Vol. 25, № 9. – P.2076.
Pioglitazone after ischemic stroke or transient ischemic attack / W.N. Kernan [et al.] // The New England Journal of Medicine. – 2016. – № 374. – P.1321–1331
